BioAge Labs

Update in progress

BIOA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on metabolic and aging-related diseases. Its platform uses human datasets to identify targets from aging-driven molecular changes. Lead candidate BGE-102 is an orally available, brain-penetrant NLRP3 inhibitor in Phase 1 for atherosclerotic cardiovascular disease, diabetic macular edema, and geographic atrophy. It also develops APJ agonists for obesity with oral and parenteral options. Based in Emeryville, CA, and partnered with Novartis to identify novel aging targets.

Company score

Sentiment: -0.05; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive